1772-1773 / 2351
Conclusions and take home mesage
Cetuximab does not seem to increase the risk of RT mucositis but acute
grade 4 dermatitis has been described.
Systemic cutaneous toxicity of anti-Epidermal Growth Factor Receptor
i hibit
b t t d d di
th
t
ith
n ors can e rea e epen ng on e symp oms w
- antiacne or antirosacea cream (erythromycin or clindamycin gel)
- topical corticosteroids,
- antihistaminic if itching,
- oral tetracycline (minocycline 100 mg/day)
Around 60% of the patients will develop long term xerostomia. The
incidence of xerostomia could be reduced by IMRT.